Arcus Biosciences, Inc.
RCUS· NYSE
Released Aug 5, 2021, after the close
10-Q filed Aug 5, 2021, 36 days after period end · 0001564590-21-041611
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $9.46M | $1.75M | $1.75M | $1.25M |
| Net Income | -$75.97M | -$45.07M | -$28.09M | -$13.53M |
| EPS Diluted |
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
| -$1.09 |
| -$0.93 |
| -$0.64 |
| -$0.32 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.